Quince Therapeutics (QNCX) grants 200,000 stock options to president

Rhea-AI Filing Summary

Quince Therapeutics, Inc. reported that its President, Charles S. Ryan, received an employee stock option grant on January 23, 2026. The option gives him the right to buy 200,000 shares of common stock at an exercise price of $3.08 per share, with no cash paid for the grant itself.

The option vests in equal monthly installments over four years. According to the terms, 1/48th of the total shares vested on the grant date, and the remaining portions vest on the first day of each subsequent month so that all 200,000 shares are fully vested by December 1, 2029. After this grant, he directly beneficially owns 200,000 derivative securities in the form of these options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Charles S.

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$3.08	01/23/2026		A		200,000		(1)	01/23/2036	Common Shares	200,000	$0	200,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.

	/s/ Brendan Hannah as attorney-in-fact for Charles Ryan	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Quince Therapeutics (QNCX) disclose in this Form 4?

Quince Therapeutics disclosed that its President, Charles S. Ryan, received an employee stock option grant for 200,000 shares of common stock on January 23, 2026.

What are the key terms of the stock option granted to the Quince Therapeutics president?

The option allows the President to buy 200,000 common shares at an exercise price of $3.08 per share. The grant itself had a $0 price for the derivative security.

How does the 200,000-share stock option for QNCX vest over time?

The option vests in 48 equal monthly installments. 1/48th vested on the January 23, 2026 grant date, and the remaining portions vest on the 1st day of each subsequent month, fully vesting by December 1, 2029.

How many derivative securities does the Quince Therapeutics president own after this transaction?

Following this transaction, the President beneficially owns 200,000 derivative securities, consisting of the employee stock options reported, held in direct ownership form.

Does this Form 4 for QNCX indicate any stock was bought or sold in the market?

No market purchase or sale of common stock is shown. The filing reports an option grant, giving the right to buy shares at $3.08 per share in the future, subject to vesting.

Who is the reporting person in this Quince Therapeutics Form 4 and what is their role?

The reporting person is Charles S. Ryan, who is identified as an officer of Quince Therapeutics, Inc., serving in the role of President.